Royalty Pharma Secures Shareholder Approval for $1.1 Billion Manager Acquisition

Royalty Pharma plc has received a striking approval of 99.9% from its shareholders for the transition to an internal corporate structure by acquiring its previously external manager. This strategic move is projected to save the company over $1.6 billion over the next decade, with significant annual cash savings starting from 2026. Royalty Pharma aims to enhance shareholder alignment, governance, and economic returns. The total transaction value, approximately $1.1 billion, includes equity and cash payments alongside the assumption of debt, and will internalize the employees of the Manager into Royalty Pharma. Founded in 1996, Royalty Pharma is a leader in biopharmaceutical royalties. This move marks the closure of a longstanding external management arrangement, aiming to streamline operations and bolster shareholder value.